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We are deeply saddened by the passing of Professor
Bongani Mayosi. Bongani was one of the inaugural
board members of Pilot and Feasibility Studies. He con-
tributed greatly to the design and conduct of pilot and
feasibility studies in cardiovascular research. Before his
untimely death on Friday, July 27, 2018, he rose rapidly
through the ranks to become a top cardiologist and one
of the premier medical researchers in South Africa,
Africa and the World
Born in Mthatha, Eastern Cape Province on January
28, 1967, Bongani Mawethu Mayosi followed in his fa-
ther’s footsteps to become a doctor. He trained at the
now Nelson R. Mandela School of Medicine at Univer-
sity of KwaZulu-Natal, where he received his M.B., Ch.B.
(Cum Laude) in 1989 and also met his wife, Professor
and Head of Dermatology, Nonhlanhla Khumalo, in
their first week of medical school. In 1990, the pair made
their way to Port Elizabeth to work at the Livingstone
Hospital as interns, before moving to Cape Town to es-
tablish long-term careers. After completing his specialist
training in internal medicine and cardiology at the Uni-
versity of Cape Town (UCT), Professor Mayosi moved
to Oxford University, UK, on a prestigious Nuffield
Medical Fellowship where he completed a D.Phil. in car-
diovascular genetics at the Wellcome Trust Centre for
Human Genetics.
Upon returning to Cape Town in 2001‚ Professor
Mayosi assumed research‚ teaching, and clinical respon-
sibilities in Internal Medicine and Cardiology at UCT
and Groote Schuur Hospital, coincidentally the place in
which the world’s first human heart transplant took
place during the year of his birth. Five years later‚ at the
age of 38‚ he became the first black faculty member to
be made Professor and Head of the Department of
Medicine.
Contributions to Pilot and Feasibility Studies
Overall, Bongani believed strongly in the value of asses-
sing feasibility to ensure the successful conduct of main
trials—something that he applied in the design of his
IMPI (investigation of the management of pericarditis)
trial to determine the effects of prednisolone and Myco-
bacterium indicus pranii (Mw) immunotherapy on the
composite outcome of death, constriction, or cardiac
tamponade requiring pericardial drainage in patients
with TB pericardial effusion [1]. He was among the first
international colleagues to answer the call to serve on
the editorial board of the journal when it was launched
in 2015. Bongani truly believed in the mission of the* Correspondence: thabanl@mcmaster.ca1McMaster University, Hamilton, ON, Canada
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journal—to provide dedicated space for both the report-
ing of feasibility and pilot studies, as well as discussion
of methodological issues around the planning of future
large-scale definitive studies—as a way to advance health
not only in South Africa but around the world. Despite
his busy schedule as Dean of the Faculty of Health
Sciences at UCT, Bongani still took time to review man-
uscripts for Pilot and Feasibility Studies, which he did as
recently as in June 2018. We owe the success of the
journal, in part, to the dedication of scientists like
Bongani.
Contributions to mentoring and research capacity
building in Africa
Perhaps one of Bongani’s most remarkable legacies is his
dedication to mentoring junior clinician scientists and
building research capacity in Africa [2]. In 2007, citing
difficulties faced during his own research training, this
visionary played a leading role in the launch of the South
African National Health Scholars Programme (1000 Ph.D.
scholarships during a 10-year initiative) [3]. With an eye
on the future of building research capacity in hopes of im-
proved clinical outcomes, he maintained a thriving trans-
lational research lab. Google “bongani mayosi and
mentoring” you will get over 4000 hits, most of which are
commentaries, press or media news, tributes, or senti-
ments expressed by the many people lucky to have known
him or have been mentored by him. He was a natural born
teacher who made a deliberate decision to share his know-
ledge with others.
Bongani was a true genius: his calmness was soothing
in the face of chaos; his humility was inspirational; his
scientific intuition and insights were brilliant; and his
professional and personal instincts, truly amazing. These
are the qualities that made him a magnet for young re-
searchers who came from all over the African contin-
ent—Nigeria, Botswana, Lesotho, Swaziland, Malawi,
Zambia, Kenya, Uganda, and Zimbabwe—to have the
privilege of being mentored by one of its top cardiolo-
gists. One of us (MN), who is now head of the Division
of Cardiology at UCT, is one of the grateful beneficiaries
of his mentorship.
Contributions to cardiovascular science
While Professor Christian Barnard put South Africa on
the map by performing the world’s first heart transplant
on December 3, 1967 [4], Professor Bongani Mayosi made
his country famous for its global leadership in cardiovas-
cular clinical research. A core part of his research mission
was to prioritize cardiovascular diseases of poverty which
(a) disproportionately affected Africans and (b) had been
neglected by the global research agenda. In 2008, he led
the multinational IMPI trial which investigated the use of
steroids in treating tuberculosis pericarditis [1]. IMPI
found that among patients with tuberculous pericarditis,
steroids (i) do not reduce the incidence of the combined
outcome of death, cardiac tamponade, or constriction; (ii)
increase the incidence of HIV-associated cancer; (iii) re-
duce the incidence of constrictive pericarditis and
hospitalization regardless of HIV status; and (iv) Mw is in-
effective but increases the incidence of HIV-associated
cancer. The findings of IMPI have set a new standard for
clinical practice in the world. He then led the first phase
of a large-scale‚ multinational study of rheumatic heart
disease, the leading cause of heart disease among school
children, in Africa [5, 6]. Venturing into yet another clin-
ical challenge, Professor Mayosi was perplexed by how
highly athletic persons could experience life-threatening
abnormal rhythms of the heart during routine exercise.
His team, joined by others across the globe, proposed
CDH2 mutations as novel genetic causes of arrhythmo-
genic right ventricular cardiomyopathy (ARVC). CDH2
encodes cadherin 2 (also known as N-cadherin), a protein
that plays a vital role in cell adhesion, making it a biologic-
ally plausible candidate gene in ARVC pathogenesis. Little
did we know that this groundbreaking discovery was to be
his swansong [7].
Having co-authored over 330 peer-reviewed publica-
tions, Bongani’s contributions to science are truly re-
markable. He received many honors and awards during
his stellar career. Those that he particularly cherished in-
clude: South Africa’s highest presidential award, the
Order of Mapungubwe in Silver (in recognition of excel-
lent contributions to medical science) in 2009; the Na-
tional Science and Technology Foundation—BHP
Billiton Award (To an individual for outstanding contri-
bution to Science Engineering Technology and Innovation
Through Management and related activities over the pre-
vious 5–10 years or less) in 2012; the National Research
Foundation (NRF) Science Team Award in 2017. This
award recognizes that it is often teams working collab-
oratively that produce the types of research that pro-
foundly benefit society. This was the case for Professor
Mayosi’s discovery of the gene responsible for ARVC,
which came after 20 years of research and international
collaboration across four countries on three continents;
the Honorary Fellowship of Wolfson College, University
of Oxford (to individuals whom they particularly value
and admire for their outstanding distinction in their
field); and in 2016, an NRF “A” Rating (for researchers
who are unequivocally recognized by their peers as lead-
ing international scholars in their field for the high qual-
ity and impact of their recent research outputs). Finally,
in 2017, he became the only African admitted that year
to the US Academy of Medicine.
Bognani was a true global citizen, who always carried
the torch for South Africa and Africa. His role as a mem-
ber of editorial boards of several national and international
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journals, included that of Associate Editor for Africa of
Circulation. He was also the President of the College of
Physicians of South Africa, Chairman of the South African
National Health Research Committee, President of the
Pan-African Society of Cardiology (PASCAR), and Chair-
man of the Advisory Committee of Health Research and
Development of the World Health Organization—Africa
Region. In 2007, he convened the historic first “All Africa,
All Heart” Conference of PASCAR that was held in
Nairobi, Kenya from 13 to 16 May 2007—followed by
similar meetings in Abuja, Nigeria (2009); Kampala,
Uganda (2011); Dakar, Senegal (2013); and Balaclava,
Mauritius (2015)—that revitalized the cardiovascular
medicine community on the African continent.
Professor Mayosi was the South African lead investiga-
tor on many international studies that have contributed
to a better understanding of cardiovascular disease pre-
vention, treatment, and management globally. These in-
clude: IMPI trial [1] and the PURE [8], PASCAR [9],
MANAGE [10], and REMEDY [5, 6] studies. He played
a leading role in establishing the Global Rheumatic
Heart Disease Registry (the REMEDY study) to provide
information on the clinical characteristics, treatment,
outcomes, and barriers to care of rheumatic heart dis-
ease. Being the first and largest multi-center study of
rheumatic heart disease, REMEDY showed that this dis-
ease of the young is associated with a heavy burden of
complications and identified major gaps in the use of
proven interventions such as penicillin for secondary
prophylaxis and oral anticoagulants for those at risk for
stroke [5, 6]. Professor Mayosi’s research is documented
in many leading, high-impact medical journals such as
NEJM, JAMA, Lancet, BMJ, Circulation, European Heart
Journal, the American Journal of Human Genetics,
Heart, American Heart Journal, and PloS ONE, to men-
tion only a few. His health research collaborations span
the entire globe and include researchers from 39 coun-
tries. In all these efforts, Bongani always extended op-
portunities to other African researchers. For example,
his IMPI trial included seven African countries (South
Africa, Zimbabwe, Mozambique, Malawi, Sierra Leone,
Nigeria, and Kenya).
Personal reflections
Bongani, a true family man, is survived by his wife, Pro-
fessor Nonhlanhla Khumalo, Head of the Dermatology
Department at UCT—who is a renowned researcher and
educator in her own right, and three daughters, Nosipho
‚ S’vuyile Mayosi-Manana, who followed in her parents
and grandfather’s footsteps to become a doctor, and
Camagu. In January this year, Nonhlanhla organized a
surprise party for him in the majestic mountains of Stel-
lenbosch in Cape Town to celebrate his 51st birthday
with friends and family. All those who attended effused
about his contributions to their own personal and career
growth and development, as well as his impact on medi-
cine in South Africa and beyond as a researcher, educa-
tor, and administrator. They talked about his human
qualities which were so attractive to the many who as-
pired to be like him: his work ethic, kindness, generosity,
mentorship style, and his infectious smile! These are
some of Bongani’s priceless attributes which we will
miss, but that will long be cherished in our hearts.
Sadly, a man who touched and inspired so many per-
sonally struggled with the isolation and bleakness of a
mental illness. After his death, his family released a
statement including the following: “In the last two years
he has battled with depression and on that day took the
desperate decision to end his life” [11].
On the heels of suicides of several other prominent,
accomplished, renowned personalities globally, Professor
Mayosi’s death confirms that mental illness does not play
favorites. No one is immune, regardless of age, race, gen-
der, socio-economic status, or profession. We know that
depression and suicide rates among health professionals
are even higher than those in the general population [12,
13]. In Africa, discussion about mental health remains
taboo because of stigma. The openness of Professor
Mayosi’s family in disclosing the cause of his death was
commendable and offers a start. Suicide leaves survivors
with so many questions. There is a need for ongoing re-
flection on the death of Professor Mayosi, in order to
learn lessons about how such tragic events can be pre-
vented, detected, and managed better within the aca-
demic environment [14]. We have a collective
responsibility as individuals working within an often
fraught health care system to tackle these stigmatizing
issues head-on, implement evidence-based prevention
strategies (viz. education, confidential screening, and
early intervention), and increase awareness of factors
that offer protection from suicidal behavior and that
promote wellness and recovery. This will require clinical
and academic leadership at the highest level to break the
culture of silence and support action.
Professor Mayosi was one of a kind; his untimely pass-
ing is a tragedy of immense proportions. We can cele-
brate his life and honor his legacy by continuing with
those academic, research, and training programs he was
so passionate about. Rest in peace, Bongani: our brother,
friend, colleague, and life mentor.
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